Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Michael E. Hurwitz(Yale University), Erika Puente-Poushnejad(Nektar Therapeutics (United States)), Adi Diab(Cleveland Clinic), Ute Hoch(University of Arizona), David Chien(Nektar Therapeutics (United States)), Mehmet Asım Bilen(Emory Healthcare), Giovanni Grignani(Candiolo Cancer Institute), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Mary Tagliaferri(Nektar Therapeutics (United States)), Arjun Vasant Balar(NYU Langone Health), Daniel C. Cho(NYU Langone Health), Lily Tang(Nektar Therapeutics (United States)), Danni Yu(National Heart Lung and Blood Institute), Mario Sznol, Jonathan Zalevsky(Nektar Therapeutics (United States)), Sue Currie(St. Paul's Hospital), Arkopal Choudhury(Nektar Therapeutics (United States))
Cited by 27
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k